Fibroblast growth factor-23 (FGF-23) is a bone-derived hormone that activates FGFR/α-Klotho binary complexes in the kidney renal tubules to regulate phosphate reabsorption and vitamin D metabolism. The objective of this review is to discuss the emerging data that show that FGF-23 has functions beyond regulation of mineral metabolism, including roles in innate immune and hemodynamic responses. Excess FGF-23 is associated with inflammation and adverse infectious outcomes, as well as increased morbidity and mortality, particularly in patients with chronic kidney disease. Enhancer elements in the FGF-23 promoter have been identified that mediate the effects of inflammatory cytokines to stimulate FGF-23 gene transcription in bone. In addition, inflammation induces ectopic expression of FGF-23 and α-Klotho in macrophages that do not normally express FGF-23 or its binary receptor complexes. These observations suggest that FGF-23 may play an important role in regulating innate immunity through multiple potential mechanisms. Circulating FGF-23 acts as a counter-regulatory hormone to suppress 1,25D production in the proximal tubule of the kidney. Since vitamin D deficiency may predispose infectious and cardiovascular diseases, FGF-23 effects on innate immune responses may be due to suppression of 1,25D production. Alternatively, systemic and locally produced FGF-23 may modulate immune functions through direct interactions with myeloid cells, including macrophages and polymorphonuclear leukocytes to impair immune cell functions. Short-acting small molecules that reversibly inhibit FGF-23 offer the potential to block pro-inflammatory and cardiotoxic effects of FGF-23 with less side effects compared with FGF-23 blocking antibodies that have the potential to cause hyperphosphatemia and soft tissue calcifications in animal models. In conclusion, there are several mechanisms by which FGF-23 impacts the innate immune system and further investigation is critical for the development of therapies to treat diseases associated with elevated FGF-23.
FiGuRe 1 | Mechanisms of fibroblast growth factor-23 (FGF-23) effects to impair innate immune responses. (A) FGF-23 bone-kidney-cardiac-immune axis.
FGF-23 is produced by osteoblasts/osteocytes in bone in response to local and systemic factors and targets the kidney to create multiple endocrine networks (4, 13) in bone, including (1) an FGF-23 vitamin D counter-regulatory loop (4, 14) ; (2) a calcium-FGF-23 endocrine loop, where calcium stimulates FGF-23 in bone and FGF-23 stimulates calcium reabsorption in the DT (15, 16) ; (3) a bone-kidney axis, where FGF-23 is regulated by factors involved in extracellular matrix mineralization to coordinate renal phosphate handling (1) . In addition, there is a bone-renal-cardiac axis that augments hemodynamic responses through a feed forward bone-cardio-renal loop, where angiotensin II (Ang II) stimulates FGF-23 production in bone (17) and FGF-23 suppresses Ace2 in the kidney (18) inactivating mutations of Dmp1 (5, 7)-ARHR2-caused by inactivating mutations in Enpp1 (6-10)-and Raine syndromecaused by inactivating mutations in FAM20C (11, 12) . Increased FGF-23 is the result of either increased gene transcription or diminished cleavage of FGF-23 in these disorders.
ROLe OF FGF-23 iN iNFLAMMATiON
There are emerging data that FGF-23 may have effects on immune responses. Vitamin D, which is regulated by FGF-23, has welldescribed effects on both innate and adaptive immunity (20) (21) (22) . Vitamin D has an overall effect to enhance innate immune responses and exert anti-inflammatory effects through local and systemic effects. Evidence that FGF-23 may have an overall impact on immunity comes from the association between elevated FGF-23 levels and inflammation. FGF-23 is increased in inflammatory bowel disease (23) and chronic kidney disease (CKD) (4) . In CKD, elevated FGF-23 initially functions to maintain mineral homeostasis, but persistent elevations are maladaptive and associated with increased morbidity and mortality (24) (25) (26) , cardiovascular disease (26) (27) (28) (29) (30) , inflammation, and infections (31, 32) . Infections, most commonly caused by infected catheters and pneumonia (33) , are second to cardiovascular disease in causing death in CKD (34) and are >100-fold higher than the general population. Recent clinical association studies suggest that elevated FGF-23 contributes to an increase in susceptibility or severity of infections in CKD. Moreover, elevated FGF-23 levels correlated with increased IL-6, TNFα, CRP, fibrinogen, and severe inflammation in CKD patients (31, 35) . In a CKD mouse model of bacterial pneumonia, FGF-23 administration exacerbated disease severity and its inhibition improved outcomes (19 There is compelling data that FGF-23 targets macrophages. Several studies have demonstrated that macrophages and DCs express FGFR1 and inflammatory stimuli upregulates α-Klotho expression in macrophages to reconstitute FGFR-α-Klotho signa ling (3, 37) . Stimulation of these cells with FGF-23 resulted in induction of TNF-α mRNA and protein expression in primary macrophages as well as macrophage cell lines through activation of binary FGFR/α-Klotho complexes (3, 37) . In addition, the ability of FGFR inhibitors to block FGF-23 signaling in macrophages confirms that the canonical FGFR/Kl signaling pathway is active in macrophages (3).
If FGF-23 is directly affecting innate immune responses, animal models with elevated FGF-23 should exhibit abnormal host responses even in the absence of CKD. Indeed, a sterile inflammation model to induce the infiltration of peritoneal macrophages with thioglycolate shows that Hyp mice have increased FGF-23 expression in macrophages (3). Macrophages isolated from Hyp mice expressed higher levels of FGF-23 and Klotho compared with WT controls. Hyp macrophages also had increased basal ERK activation and increased TNF-α mRNA, consistent with activation of FGFR/αKl signaling. Serum levels of TNF-α were increased consistent with the pro-inflammatory phenotype [i.e., kidney inflammation (18) and cardiovascular abnormalities in Hyp mice (55)]. These data support the hypothesis that locally produced and circulating FGF-23 activate immune cells in the inflammatory milieu (3, 43) , leading to adverse outcomes (56) . In this scenario, infection with bacteria stimulates the production of FGF-23 locally in M1 activated macrophages which also upregulate FGFR/α-Kl complexes (3) . Autocrine stimulation of the M1 cells with FGF23 amplifies TNF production and inhibits the transition to a wound healing M2 phenotype, resulting in excess tissue damage and increased morbidity and mortality ( Figure 1B) .
Based on these findings, a new hypothesis proposes that FGF-23 actions on innate immunity are mediated by activation of reconstituted canonical FGFR/α-Kl receptors in tissue macrophages during infections by both systemic and local production of FGF-23 ( Figure 1B) (3, 19, 37, 43) ROLe OF α-KLOTHO AND SOLuBLe KLOTHO (sKl) iN iNFLAMMATiON α-Klotho gene has two transcripts that encode a long type I transmembrane (TM) protein containing KL1 and KL2 domains and a short secreted protein containing only a single KL domain (57) . The ~130-kDa TM protein is an obligate co-receptor for binding of FGF-23 to FGFRs (2, 58) . Ectodomain shedding by ADAM10 and ADAM17 generates a circulating α-Klotho isoform that lacks the TM domain (59) . The short secreted ~60-kDa isoform (s-KL) is generated by the alternative spliced transcript. Similar sized as soluble KL1 and KL2 fragments are also generated by additional post-translational cleavage of the shed isoform (57, 60) . The ~60-kDa s-KL gene product emerged during evolution before FGF-23 and likely has FGF-23 independent functions, including antiaging, anti-inflammatory, and anti-fibrotic effects due to actions of secreted forms of KL to inhibit Wnt, IGF-1, and TGF-β signaling (61) (62) (63) (64) (65) . Since excess FGF-23 is associated with decreased expression of α-Klotho in the kidney and circulating Kl, it is difficult to determine if the adverse effects attributed to excess FGF-23 are actually caused by Klotho deficiency. Indeed, Klotho depletion is associated with increased inflammation in multiple experimental models.
A recent study showed that renal Klotho mRNA and protein were significantly decreased leading to increased inflammation in kidney of the db/db mouse model of diabetes (66) . Addition of sKl or overexpression of α-Klotho suppressed NF-κB activation and subsequent production of inflammatory cytokines in response to TNF-α stimulation in vitro. Klotho serves as an anti-inflammatory modulator, which negatively regulates the production of NF-κB-linked inflammatory proteins via a mechanism that involves phosphorylation of Ser 536 in the transactivation domain of RelA (66) . Thus, distinguishing between FGF-23 and α-Klotho-dependent effects are important, because Klotho administration would correct abnormalities caused by FGF-23 suppression of Klotho.
FGF-23 ReGuLATeS HeMODYNAMiC ReSPONSeS TO COuNTeR THe HYPOTeNSive eFFeCTS OF iNFLAMMATiON
Could FGF-23 effects regulate renal process that have cardiovascular effects, be linked to inflammatory responses (53, 67) ? For example, FGF-23 upregulates NCC in the DT leading to hypertension and suppression of aldosterone levels (15, 16, 55) . FGF-23 administration suppresses ACE2 and αKl expression in the kidney, which could potentially cause left ventricular hypertrophy by enhancing the response to Ang II and/or decreasing circulating sKl (68) . From a teleological perspective, FGF-23 control of blood pressure may serve to attenuate the hypotensive effects of inflammation, or alternatively account for the link between inflammation and hypertension (69) . 
THeRAPeuTiC POTeNTiAL OF FGF-23 ANTAGONiST
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